Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.37 |
| ▸ | PPARG | P37231 | 5/20 | 0.36 |
| ▸ | PPARA | Q07869 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 5/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 2/20 | 0.34 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.34 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PTGES | O14684 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 3/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4923444 | 0.89 | MAPT (0.42) | MAPTSMN1; SMN2THRBPOLBPTGES | |
| SCHEMBL4916920 | 0.88 | ELANE (0.41) | ELANEPPARGPPARAMAPTSMN1; SMN2 | |
| SCHEMBL4916692 | 0.85 | SMN1; SMN2 (0.41) | MAPTSMN1; SMN2THRBTP53LMNA | |
| SCHEMBL3010781 | 0.80 | ELANE (0.44) | ELANEPPARGPPARAMAPTSMN1; SMN2 | |
| SCHEMBL4923569 | 0.79 | PPARG (0.47) | PPARGPPARAPTGES | |
| SCHEMBL4923349 | 0.78 | ELANE (0.38) | ELANEPPARGPPARAMAPTSMN1; SMN2 | |
| SCHEMBL4925680 | 0.77 | PPARG (0.48) | PPARGPPARAPTGES | |
| SCHEMBL4924017 | 0.76 | PPARG (0.45) | PPARGPPARAPTGES | |
| SCHEMBL4925311 | 0.76 | PPARG (0.42) | PPARGPPARAMAPTSMN1; SMN2THRB | |
| SCHEMBL4924948 | 0.74 | MAPT (0.47) | MAPTSMN1; SMN2THRBPOLBPTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249091-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249091-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, IDO2, ARG1 | ELANE 648/4885PPARG 2586/4885PPARA 3339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.